BEIJING, Aug. 12, 2015 (GLOBE NEWSWIRE) -- BeiGene, Ltd., a clinical-stage biopharmaceutical company focused on developing molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced the appointment of Dr. Howard Liang as its Chief Financial Officer and Chief Strategy Officer. Dr. Liang has more than 20 years of combined experience on Wall Street as an analyst covering the biotechnology and pharmaceutical sectors and as a scientist in the biopharmaceutical industry. Dr. Liang will be based in BeiGene's U.S. office in the Greater Boston area.
"We are thrilled and fortunate to have Howard join the BeiGene team," said John V. Oyler, Chief Executive Officer. "His breadth of biotechnology knowledge from a financial and drug discovery experience is particularly well suited to the current and future needs of our company as we build a global biopharmaceutical company."
"I am excited to contribute my skills and experience to BeiGene. The company is at a critical point in its growth," said Dr. Liang. "I look forward to being part of the company's experienced management team as we strive to translate the strength of their science into meaningful benefits for cancer patients."
Prior to joining BeiGene, Dr. Liang spent 10 years at Leerink Partners, where he was a Managing Director and head of biotechnology equity research. Dr. Liang has also held senior biotechnology analyst positions at A.G. Edwards and JMP Securities. He began his career on Wall Street at Prudential Securities, where he was an associate analyst covering major and specialty pharmaceuticals.
Before joining Wall Street, Dr. Liang spent eight years at Abbott Laboratories, where he was a senior scientist and a member of one of the industry's leading structure-based drug discovery teams. During his career as a scientist, Dr. Liang authored a review and 13 papers including 6 in Nature, Science, and Proceedings of the National Academy of Sciences.
Dr. Liang obtained his MBA and Ph.D. in Biochemistry and Molecular Biology, both from the University of Chicago, and his B.S. in Chemistry from Peking University.
BeiGene is a global, clinical-stage, research-based company focused on targeted and immuno-oncology therapeutics. With a team of 175 scientists and staff, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is working to create combination solutions that will have both a meaningful and lasting impact on cancer patients. For more information, please visit our website at www.beigene.com.
CONTACT: Media/Investor Contact: Xin Huang US: +1 917-617-4653 China: +86 185-1406-3050 firstname.lastname@example.org